Nulojix (belatacept) / BMS - LARVOL DELTA

The Rise of DSA Without AMR: When and How to Intervene (ISHLT 2026) - "3) If treatment is pursued, which approach is most rational - anti-CD38 (daratumumab), co-stimulation blockade (belatacept), anti-IL-6 (tocilizumab), anti-CD20 (rituximab), or proteasome inhibition (bortezomib)? 4) Should maintenance immunosuppression be modified to prevent further antibody evolution? At the end of the talk there will be a vote for best treatment from the audience."

IO biomarker • Transplantation

SYMPOSIUM 20. The Antibody Strikes Back: Cases of Subclinical to Refractory AMR in Heart Transplantation (ISHLT 2026) - "Emerging strategies such as HALT (hepatic antibody absorption), next-generation biomarkers (donor-derived cfDNA, tissue GEP), and novel therapies (daratumumab, tocilizumab, proteasome inhibitors, belatacept, and ECP) will be discussed. Audience engagement will be emphasized through live voting on management decisions, fostering dialogue on controversies and best practices across the spectrum of AMR care."

Clinical • Antibody-mediated Rejection • Transplantation

Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection. (PubMed, Am J Transplant) - "No thrombotic events were observed. While the prespecified primary endpoint to prevent composite efficacy failure was not met among patients who completed this study, dazodalibep and belatacept dual biologic treatment was generally safe, well tolerated, and effective as the sole maintenance antirejection therapy."

Journal • Antibody-mediated Rejection • Immunology • Solid Organ Transplantation • Transplant Rejection • Transplantation • CD40LG • CD80

Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - (clinicaltrials.gov) - P4 | N=44 | Not yet recruiting | Sponsor: University Hospital, Rouen | Trial completion date: Jan 2028 ➔ Dec 2028 | Trial primary completion date: Jan 2028 ➔ Dec 2028

Trial completion date • Trial primary completion date • Nephrology • Renal Disease • Transplantation

Torque teno virus load and antiviral T-cell immune response after belatacept initiation in kidney transplant recipients (ESCMID Global 2026) - No abstract available

Clinical • Transplantation

Immunogenicity of the bivalent pre-F respiratory syncytial virus (RSV) vaccine in kidney transplant recipients with and without belatacept as maintenance immunosuppressive treatment (ESCMID Global 2026) - No abstract available

Clinical • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

Predictors of EBV Viremia in Belatacept Treated Heart Transplant Recipients (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Transplantation

Belatacept and Transcriptomic Immune Modulation in Heart Transplantation (ISHLT 2026) - "Abstract is embargoed at this time."

Immune Modulation • Immunology • Transplantation

Use of Belatacept in Recipients of Lung Transplantation with Refractory Cytopenias: A Case Series (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Hematological Disorders • Transplantation

The Role of Belatacept-Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation. (PubMed, Transpl Infect Dis) - "Careful selection of KT for belatacept-use is recommended in older recipients (≥ 55 years) due to the increased hazard of mortality, CMV, and EBV DNAemia."

Journal • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation

ATTAIN: Daratumumab and Belatacept for Desensitization (clinicaltrials.gov) - P1/2 | N=19 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Transplantation

Efficacy and Safety of Belatacept in Heart Transplant Recipients - Invited Response to a Letter to the Editor. (PubMed, J Heart Lung Transplant) - No abstract available

Journal • Transplantation

Belatacept in thoracic transplantation: Safety signals from lung recipients. (PubMed, J Heart Lung Transplant) - No abstract available

Journal • Transplantation

Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Nantes University Hospital | Trial completion date: Jan 2026 ➔ Jan 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Renal Disease • Transplantation

Contemporary approach to desensitization: Targeted therapies for HLA sensitized pediatric heart transplant candidates - Study design and rationale. (PubMed, JHLT Open) - "Recent adult studies show that a dual approach with Carfilzomib (CFZ), a proteasome inhibitor, and Belatacept (BELA), a costimulation blocker, reduces class I and II HLA antibodies (Abs). The HLA core will measure antibody response through MFIs, titers, and cPRA, while the mechanistic core will use advanced investigations to support the trial's clinical endpoints. This multicenter study aims to establish a transformative, standardized approach to desensitization and antibody evaluation."

Clinical • Journal • Antibody-mediated Rejection • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Oncology • Pediatrics • Transplantation

Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression (clinicaltrials.gov) - P4 | N=25 | Completed | Sponsor: University of Texas Southwestern Medical Center | Recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Jul 2025 | Trial primary completion date: Dec 2025 ➔ Jul 2025

Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Transplantation

Co-Stimulatory Blockade and Infectious Risk in Solid Organ Transplantation. (PubMed, Am J Transplant) - "Belatacept, the most extensively studied agent, has been associated with improved allograft function and reduced donor-specific antibody formation while associated with increased risk of acute, early graft rejection and increased risk for infections due to cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Pneumocystis jirovecii...Recently, immunosuppression for clinical xenotransplantation has included costimulatory blockade as a component of generally complex immunosuppressive regimens; intensive microbiological surveillance will provide insights into any associated xenozoonotic infections. Successful integration of costimulatory blockade in allotransplantation and clinical xenotransplantation require further prospective trials coupled with robust microbiological surveillance."

Journal • Review • Cognitive Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Infectious Disease • Oncology • Solid Organ Transplantation • Transplant Rejection • Transplantation • CD40LG

Dual Targeting of B Cell Compartments Using Belatacept and Daratumumab in Highly Sensitized Kidney Transplant Candidates: A Mechanistic Proof-of-Concept desensitization Trial. (PubMed, Am J Transplant) - P2 | "Dual targeting of T/B-cell co-stimulation and PC using belatacept and daratumumab is a safe and mechanistically effective approach for desensitization in highly sensitized kidney transplant candidates. These findings support further investigation in larger trials."

Journal • Transplantation

Adjuvant IL-15 Blockade Significantly Improves Survival in a CD28-based Immunosuppression Protocol of Pig-to-nonhuman Primate Renal Xenotransplantation. (PubMed, Transplantation) - "These findings deepen our understanding of NK cell subsets and their potential contributions to xenograft injury and suggest that targeted modulation of NK cell populations can enhance xenograft outcomes in a preclinical pig-to-rhesus macaque model of renal xenotransplantation."

Journal • Transplantation • IL15 • NCAM1

Immunosuppressive Therapy in Pediatric Kidney Transplantation: Evolution, Current Practices, and Future Directions. (PubMed, Biomedicines) - "Modern regimens centered on tacrolimus, mycophenolate mofetil, and risk-adapted induction have substantially reduced acute rejection and improved graft survival...Insights from recent trials including steroid minimization, everolimus-based regimens, and selective Belatacept use highlight opportunities for more individualized, risk-adapted therapy. Future efforts must prioritize precision approaches supported by biomarkers, multicenter collaboration, and long-term follow-up. Overall, contemporary trends support a shift toward tailored immunosuppression that balances efficacy with safety to optimize outcomes in pediatric KTx recipients."

Journal • Chronic Kidney Disease • Infectious Disease • Nephrology • Pediatrics • Transplant Rejection • Transplantation • IL2

De Novo Psoriasis Following Belatacept Therapy in Transplant Recipients: Case Series. (PubMed, Clin Transplant) - No abstract available

Journal • Dermatology • Immunology • Psoriasis • Transplantation

World Transplant Congress 2025 Highlights: Immunosuppression. (PubMed, Transplantation) - "Belatacept-based regimens demonstrated promise across diverse patient groups, with novel approaches of costimulation blockade (eg, CD154, CD28) advancing toward clinical translation...Finally, tolerance induction through chimerism, regulatory T cells, and engineered cellular therapies highlighted pathways toward immunosuppression withdrawal. Collectively, these innovations presented at the Congress signal a transition toward safer, more personalized, and durable transplant outcomes."

IO biomarker • Journal • Antibody-mediated Rejection • Transplantation • CD40LG

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Oct 2025 ➔ Jan 2026

Trial initiation date • Antibody-mediated Rejection • Immunology • Transplant Rejection • Transplantation

Incidence of T-cell mediated rejection in obese vs non-obese kidney transplant recipients receiving belatacept maintenance therapy. (ASHP 2025) - No abstract available

Clinical • Obesity • Transplantation

Belatacept Efficacy Post-Kidney Transplant: Insights from a Retrospective Study (ASHP 2025) - No abstract available

Retrospective data • Transplantation